Menu

WIKIMEDIA, BLUERASBERRY

Dartmouth Professor Plagiarized His Colleague, University Says

H. Gilbert Welch, a health policy expert who has advocated against superfluous cancer screening, published another Dartmouth researcher’s work, according to the university administration.

Aug 20, 2018
Jef Akst

Update (September 13): H. Gilbert Welch announced his resignation from Dartmouth College today. “I feel that I can no longer participate in the research misconduct process against me—as I fear my participation only serves to validate it,” he writes in an email to colleagues, STAT News reported.

When Dartmouth College Professor H. Gilbert Welch published a paper in the New England Journal of Medicine in 2016 arguing that mammograms can lead to the treatment of non-life-threatening tumors, he was “appropriating the ideas, processes, results or words of Complainants without giving them appropriate credit,” according to a letter by Dartmouth Interim Provost David Kotz, obtained by Retraction Watch and STAT News.

Welch and his colleagues argued that mammograms are more likely to lead to unnecessary treatment than to save lives, drawing headlines from the press and citations from fellow researchers. In fact, the NEJM paper ranks in the top 1 percent of the most highly cited papers of 2016 in its field, according to Clarivate Analytics’s Web of Science. But less than a week after it was published, fellow Dartmouth faculty member Samir Soneji accused Welch of stealing his ideas and results.

In an email to Martin Wybourne, Dartmouth’s vice provost for research, Soneji said that Welch had requested a slide from one of Soneji’s lectures. Soneji added that he had explicitly requested to be a coauthor on any paper that might result from the results depicted on the slide, and said that Welch had responded it was for a class. But that result and the ideas it generated are part of what Welch and colleagues published in NEJM in 2016.

Soneji and University of California, Los Angeles, colleague Hiram Beltrán-Sánchez submitted their own manuscript on the use of mammograms to NEJM in August 2015, the researchers tell Retraction Watch, but it was rejected. And when they submitted to another journal the following fall, a peer reviewer noticed the high degree of overlap with Welch’s now-published paper.

Welch disputes the university’s finding of misconduct, arguing that the paper is a “natural progression” of his work, he tells Retraction Watch. But in his 2016 complaint email, Soneji recounts an interaction with Welch in which Welch admits to having failed to think of some of the ideas Soneji presented in a workshop Welch attended—the very same ideas included in the NEJM paper. 

Soneji and Beltrán-Sánchez issued a statement calling for the paper to be retracted, and Dartmouth sent its findings to NEJM for consideration, but the journal decided that the issue at hand is an “authorship dispute,” which is insufficient for a retraction. “We are happy to work with you and the article authors to reach a solution whereby sufficient acknowledgment is given so that the contribution of the complainant is adequately recognized,” Editor-in-Chief Jeffrey Drazen and Deputy Editor Dan Longo wrote in a response to Dartmouth administrators.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.